Percent of NBT-positive K562 cells following induction of C/EBPα
C/EBPα construct . | % NBT positive . |
|---|---|
| 42 kDa, wild-type | 87 ± 10 |
| 30 kDa | 8.1 ± 4.4 |
| Δ126-200 | 46.5 ± 19.4 |
| Δ200-256 | 86 ± 6.2 |
| BRM2 | 0 |
| BRM3 | 74 ± 10.5 |
| Vector | 0 |
| 42 kDa, wild-type* | 73 ± 8.1 |
| Δ1-70 | 34.5 ± 23.4 |
| Vector | 0 |
C/EBPα construct . | % NBT positive . |
|---|---|
| 42 kDa, wild-type | 87 ± 10 |
| 30 kDa | 8.1 ± 4.4 |
| Δ126-200 | 46.5 ± 19.4 |
| Δ200-256 | 86 ± 6.2 |
| BRM2 | 0 |
| BRM3 | 74 ± 10.5 |
| Vector | 0 |
| 42 kDa, wild-type* | 73 ± 8.1 |
| Δ1-70 | 34.5 ± 23.4 |
| Vector | 0 |
K562 C/EBPα-estrogen receptor fusion stable cell lines were treated with 1 uM β-estradiol for 3 to 4 days. At least 100 cells were counted from 2 or more clones of each line and results given ± standard deviation.
The data in the last 3 lines in the table were obtained in an independent experiment.